Emerging SARS-CoV-2 variant BA.3.2 is more poorly neutralised by responses focussed on other contemporary strains
Stuart, D.I., Screaton, G.To be published.
Experimental Data Snapshot
Starting Model: in silico
View more details
wwPDB Validation 3D Report Full Report
Macromolecule Content 
Entity ID: 1 | |||||
|---|---|---|---|---|---|
| Molecule | Chains | Sequence Length | Organism | Details | Image |
| Spike glycoprotein | 1,144 | Homo sapiens | Mutation(s): 0  | ![]() | |
Entity Groups | |||||
| Sequence Clusters | 30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity | ||||
Glycosylation | |||||
| Glycosylation Sites: 8 | |||||
Sequence AnnotationsExpand | |||||
Reference Sequence | |||||
| Ligands 1 Unique | |||||
|---|---|---|---|---|---|
| ID | Chains | Name / Formula / InChI Key | 2D Diagram | 3D Interactions | |
| NAG Download:Ideal Coordinates CCD File | AA [auth C] D [auth A] E [auth A] F [auth A] G [auth A] | 2-acetamido-2-deoxy-beta-D-glucopyranose C8 H15 N O6 OVRNDRQMDRJTHS-FMDGEEDCSA-N | |||
| Task | Software Package | Version |
|---|---|---|
| MODEL REFINEMENT | PHENIX | dev_5270 |
| RECONSTRUCTION | cryoSPARC |
| Funding Organization | Location | Grant Number |
|---|---|---|
| CAMS Innovation Fund for Medical Sciences (CIFMS) | United Kingdom | -- |
| Medical Research Council (MRC, United Kingdom) | United Kingdom | -- |